Huberman LabSupplements for Longevity & Their Efficacy | Dr. Peter Attia
CHAPTERS
- 0:00 – 14:00
Intro, Sponsors, and NAD Pathway Setup
Huberman introduces Peter Attia, outlines his credentials, and frames the episode as a deep dive into the NAD pathway and supposed longevity supplements NR, NMN, and NAD. He previews the comparison of different approaches to boosting NAD, their evidence base, and how they fit into a broader longevity framework that also includes rapamycin, metformin, and fasting.
- 14:00 – 30:30
Attia’s Longevity Framework: Behavior, Disease-Targeting Drugs, Geroprotectors
Attia reframes Huberman’s four longevity categories into three MECE buckets: essential behaviors, exogenous molecules that target specific diseases, and geroprotective molecules that target hallmarks of aging. He emphasizes that modern longevity is fundamentally about delaying chronic diseases (cardiovascular, cancer, neurodegeneration, metabolic), and that behavior is inseparable from emotional and mental health.
- 30:30 – 55:00
Rapamycin as a Model Geroprotector and Its Evidence
Attia details his personal rapamycin use, dosing, and side effects, and explains why rapamycin stands out as a geroprotective drug. He highlights robust, reproducible lifespan extension across species and ongoing dog trials, contrasting this with the weaker evidence for many other interventions.
- 55:00 – 1:21:00
Sirtuins, Caloric Restriction, and the Origin of the NAD Hype
They unpack the early yeast work on sirtuins and caloric restriction that seeded the modern NAD/sirtuin longevity story. Attia shows how early assumptions that caloric restriction works via sirtuins fell apart with better experiments, and that sirtuins and CR appear to be parallel, additive, not hierarchical, pathways.
- 1:21:00 – 1:33:00
Resveratrol and Failed Sirtuin Activators
Attia revisits the resveratrol saga as a cautionary tale about sirtuin activators and mouse models. Initial enthusiasm was based on a highly artificial high-fat mouse model with fatty liver–induced respiratory failure; subsequent rigorous testing, including via the ITP, failed to show lifespan benefits.
- 1:33:00 – 1:54:00
NAD Biology, Age-Related Changes, and Redox Potential
They dig into what NAD actually does and how it changes with age. Most NAD function is as a redox cofactor in mitochondrial energy production, not as a sirtuin substrate, and age-related NAD changes may reflect altered redox balance more than a simple deficiency that needs “topping up.”
- 1:54:00 – 2:18:00
The Case For and Against Boosting NAD (NR, NMN, Infusions)
They address the real-world question: does raising NAD via NR, NMN, or NAD drips do anything meaningful? Huberman shares his personal experiences with all three routes, while Attia points out that even if blood NAD rises, evidence that this matters for lifespan or healthspan is virtually absent.
- 2:18:00 – 2:34:00
What the Interventions Testing Program (ITP) Actually Shows
Attia uses the ITP to benchmark claims about NR and other compounds. The ITP’s rigorous multi-site mouse lifespan trials have identified only a handful of true hits (rapamycin, canagliflozin, acarbose, 17-α estradiol in males), and NR is not among them.
- 2:34:00 – 2:46:00
Human Trials on NR/NMN: Small Signals, Little Clinical Meaning
They dissect the main human NR and NMN trials that are often referenced in marketing. While some endpoints reach statistical significance (e.g., slight liver fat reduction in a subset, small boost in glucose disposal), the magnitude of these changes is too small to likely affect real-world outcomes.
- 2:46:00 – 3:04:00
A Possible Exception: Skin Cancer Risk and NAD Precursors
Attia highlights one area where NAD precursors may have a substantial, specific benefit: reducing incidence of non-melanoma skin cancers. He cautions that this needs replication but notes it might be a context where NAD supplementation makes sense for some individuals.
- 3:04:00 – 3:24:00
Biological Age Tests, Radiation Anxiety, and Perspective
They critique current biological age tests and address common fears about radiation from flights and scanners. Attia argues that most clocks are noisy and unvalidated for practical decisions, and that everyday radiation exposures are well below dangerous levels, helping contextualize real vs perceived risks.
- 3:24:00 – 3:40:00
The Critical Role of Midlife: Muscle, Power, and Reserve
They shift from molecules to midlife strategy, arguing that the 50s–70s are decisive for building physiological reserve. Strength, muscle mass, and power are much easier to build and maintain now than in late life, making consistent training in this window central to healthspan and independence in older age.
- 3:40:00 – 3:55:00
Energy with Age, Kids’ Spontaneous Activity, and Limits of Supplements
They reflect on why children have such boundless, spontaneous energy while adults become more conservative with movement and energy expenditure. They acknowledge the mystery of age-related energy declines, speculate about mitochondrial roles, and reiterate that no supplement currently rivals the impact of sleep, training, and diet on day-to-day vigor.
- 3:55:00 – 4:25:00
What Huberman and Attia Actually Take (and Why)
Both disclose their personal supplement and drug regimens, providing practical context to their theoretical positions. Attia focuses on evidence-backed disease-modifying drugs and a few plausible geroprotectors; Huberman emphasizes foundational micronutrient coverage, fish oil, creatine, and a small number of compounds with subjective or mechanistic appeal.
- 4:25:00
Final Verdict on NAD Pathway Supplements and Closing Thoughts
They converge on a clear stance: current data do not support using NR, NMN, or NAD infusions to extend human lifespan, and any healthspan benefits appear modest and context-specific. They stress intellectual honesty, willingness to change views with new data, and a strong recommendation to prioritize behaviors over boutique interventions.
Get more out of YouTube videos.
High quality summaries for YouTube videos. Accurate transcripts to search & find moments. Powered by ChatGPT & Claude AI.
Add to Chrome